These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23182701)

  • 1. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.
    Heath CH; Deep NL; Nabell L; Carroll WR; Desmond R; Clemons L; Spencer S; Magnuson JS; Rosenthal EL
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1275-81. PubMed ID: 23182701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy.
    Manyam BV; Gastman B; Zhang AY; Reddy CA; Burkey BB; Scharpf J; Alam DS; Fritz MA; Vidimos AT; Koyfman SA
    J Am Acad Dermatol; 2015 Aug; 73(2):221-7. PubMed ID: 26028524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
    Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
    Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of erlotinib as adjuvant chemoprevention in high-risk head and neck cancer patients.
    Rosenthal EL; Chung TK; Carroll WR; Clemons L; Desmond R; Nabell L
    Ann Surg Oncol; 2014 Dec; 21(13):4263-9. PubMed ID: 25001094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck.
    Tanvetyanon T; Padhya T; McCaffrey J; Kish JA; Deconti RC; Trotti A; Rao NG
    Head Neck; 2015 Jun; 37(6):840-5. PubMed ID: 24623654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy.
    Sun L; Chin RI; Gastman B; Thorstad W; Yom SS; Reddy CA; Nussenbaum B; Wang SJ; Knackstedt T; Vidimos AT; Koyfman SA; Manyam BV
    JAMA Dermatol; 2019 Apr; 155(4):442-447. PubMed ID: 30810715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
    Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
    Rusthoven KE; Feigenberg SJ; Raben D; Kane M; Song JI; Nicolaou N; Mehra R; Burtness B; Ridge J; Swing R; Lango M; Cohen R; Jimeno A; Chen C
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1020-5. PubMed ID: 20231078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Adjuvant Radiation Therapy With Survival in Patients With Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Harris BN; Pipkorn P; Nguyen KNB; Jackson RS; Rao S; Moore MG; Farwell DG; Bewley AF
    JAMA Otolaryngol Head Neck Surg; 2019 Feb; 145(2):153-158. PubMed ID: 30570645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.
    Gold KA; Kies MS; William WN; Johnson FM; Lee JJ; Glisson BS
    Cancer; 2018 May; 124(10):2169-2173. PubMed ID: 29579331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma.
    O'Bryan K; Sherman W; Niedt GW; Taback B; Manolidis S; Wang A; Ratner D
    J Am Acad Dermatol; 2013 Oct; 69(4):595-602.e1. PubMed ID: 23871719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck.
    Manyam BV; Garsa AA; Chin RI; Reddy CA; Gastman B; Thorstad W; Yom SS; Nussenbaum B; Wang SJ; Vidimos AT; Koyfman SA
    Cancer; 2017 Jun; 123(11):2054-2060. PubMed ID: 28171708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614.
    Koch WM; Ridge JA; Forastiere A; Manola J
    Arch Otolaryngol Head Neck Surg; 2009 Sep; 135(9):851-8. PubMed ID: 19770416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative combined chemotherapy and radiation therapy plus radical surgery in advanced head and neck cancer. Five-year results with impressive complete response rates and high survival.
    Slotman GJ; Doolittle CH; Glicksman AS
    Cancer; 1992 Jun; 69(11):2736-43. PubMed ID: 1571903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment results of regional metastasis from cutaneous head and neck squamous cell carcinoma.
    Jol JA; van Velthuysen ML; Hilgers FJ; Keus RB; Neering H; Balm AJ
    Eur J Surg Oncol; 2003 Feb; 29(1):81-6. PubMed ID: 12559082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
    Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
    Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
    Herchenhorn D; Dias FL; Viegas CM; Federico MH; Araújo CM; Small I; Bezerra M; Fontão K; Knust RE; Ferreira CG; Martins RG
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):696-702. PubMed ID: 20421154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
    Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
    Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck.
    Moore BA; Weber RS; Prieto V; El-Naggar A; Holsinger FC; Zhou X; Lee JJ; Lippman S; Clayman GL
    Laryngoscope; 2005 Sep; 115(9):1561-7. PubMed ID: 16148695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
    Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
    J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.